Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Eases Up On Part 11 Scope, Pulls Old Guidelines

This article was originally published in The Gray Sheet

Executive Summary

FDA will scale back enforcement of its electronic records and signatures rule (Part 11) for all FDA-regulated products while it reassesses the regulation in light of the agency's current good manufacturing practice initiative for drugs and biologics

You may also be interested in...



On The Virtual Horizon? FDA Revising Software Guidance, Part 11 Policy

Stakeholders will have an opportunity to comment on FDA's evolving policy on Part 11 electronic records regulation during a June meeting

On The Virtual Horizon? FDA Revising Software Guidance, Part 11 Policy

Stakeholders will have an opportunity to comment on FDA's evolving policy on Part 11 electronic records regulation during a June meeting

Part 11 Audit Trails, Legacy Systems Subject To FDA Enforcement Discretion

Device manufacturers must continue to validate electronic recordkeeping and signature systems under ongoing FDA part 11 enforcement discretion, according to CDRH International Staff Director Christine Nelson

Related Content

UsernamePublicRestriction

Register

MT017965

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel